These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15320728)

  • 21. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
    Skiles JW; Gonnella NC; Jeng AY
    Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative docking study and the design of potentially selective MMP inhibitors.
    Hanessian S; Moitessier N; Therrien E
    J Comput Aided Mol Des; 2001 Oct; 15(10):873-81. PubMed ID: 11918074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
    Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis.
    Leib SL; Clements JM; Lindberg RL; Heimgartner C; Loeffler JM; Pfister LA; Täuber MG; Leppert D
    Brain; 2001 Sep; 124(Pt 9):1734-42. PubMed ID: 11522576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quest for selectivity in inhibition of matrix metalloproteinases.
    Brown S; Meroueh SO; Fridman R; Mobashery S
    Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloprotease inhibitors: design from structure.
    Borkakoti N
    Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
    J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
    Wei S; Xie Z; Filenova E; Brew K
    Biochemistry; 2003 Oct; 42(42):12200-7. PubMed ID: 14567681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.
    Wada CK
    Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains.
    Zhao Y; Feng W; Yang Y; Ling L; Chen R
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):637-9. PubMed ID: 17357475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
    Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
    J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
    Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
    Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
    J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.
    Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4293-7. PubMed ID: 14643312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
    Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of potent and selective TACE inhibitors via the S1 pocket.
    Condon JS; Joseph-McCarthy D; Levin JI; Lombart HG; Lovering FE; Sun L; Wang W; Xu W; Zhang Y
    Bioorg Med Chem Lett; 2007 Jan; 17(1):34-9. PubMed ID: 17064892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.